Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine

Increasing access to Imaging Mass Cytometry in pharmaceutical and clinical research settings

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced a collaboration agreement with Navignostics AG for development of clinical research applications and service offerings using the Hyperion XTi Imaging System.

This collaboration is pivotal in the fight against cancer, emphasizing the need for precision medicine strategies and robust technologies that offer critical biological insights to guide treatment decisions. Imaging Mass Cytometry is purpose-built to clearly generate and differentiate these insights to help inform clinical outcomes, providing the opportunity to expand access to high-quality data in clinical research.

Founded in 2022, Navignostics is dedicated to revolutionizing personalized diagnostics for cancer patients. Its goal is to identify the most effective treatment for each patient by using innovative tumor analysis methods.

“We are very excited about this collaboration. Characterizing tumors using spatial single-cell proteomics enables identification of optimal treatments for an individual patient’s tumor and helps accelerate drug development by providing key insights into drug mechanisms and tumor features. Our ability to automate and standardize this process with IMC has really pushed us to where we are now, bringing novel developments into the clinical space to help inform treatment decisions for cancer patients,” said Jana Fischer, Chief Executive Officer of Navignostics.

The Hyperion XTi Imaging System is a significant advancement in clinical research, offering rapid, robust data acquisition and extended system stability essential for product and drug development. The machine learning process used by Navignostics to discover predictive patterns, and ultimately patient care, demand high throughput, dependable precision and the ability to scale that the Hyperion XTi can provide. In clinical studies, Navignostics demonstrated its ability to go from samples to data reporting in under 72 hours, with efforts to further reduce this time.